Arkolith/Insider Trading/SNDX/Form 4

Metzger Michael A

Chief Executive Officer, DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 12, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$206K
Net Open-Market Flow
-$206K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 10, 2025Sell(S)13K$15.50$206K300K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-019000) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML